ReviewGynecology and minimally invasive therapy
Exploring the Potential Value of Modulation of Cell Death in Immunotherapy of Gynecological Tumors.
Review in Gynecology and minimally invasive therapy. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cell death plays a pivotal role in a multitude of biological processes, including embryonic development, organ maintenance, aging, immune response, and autoimmunity. These processes are underpinned by distinct molecular mechanisms and have significant implications for biological systems. Currently, research on regulatory cell death (RCD) is primarily focused on apoptosis, necroptosis, pyroptosis, ferroptosis, cuproptosis, and autophagy. These pathways have been shown to play a crucial role in regulating the tumor microenvironment (TME) and influencing the clinical outcome of cancer immunotherapy. RCD exerts a dual regulatory effect on TME, releasing intracellular components and regulating the distribution of immune cells. These cells are involved in fine-tuning the antitumor immune response in the TME. The treatment of gynecological tumors frequently presents a challenge due to the lack of immunotherapeutic responsiveness. This review will focus on apoptosis, necroptosis, pyroptosis, ferroptosis, cuproptosis, and autophagy. It will explore how the molecular messengers released during these processes are involved in regulating their complex interactions with tumor tissues as well as with the immune response. It will also analyze the immunological consequences of regulated cell death and its potential impact on the future development of gynecological oncology therapy. By investigating the mechanisms of cell death, we can gain insight into their role in the development of gynecological tumors and potentially identify new therapeutic strategies to enhance the efficacy of existing treatments and advance cancer care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.